Antengene Licenses ATG-106 to K2 Therapeutics
- Antengene Corporation Limited licensed ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager for solid tumors, to K2 Therapeutics through an exclusive agreement.
- Antengene granted K2 Therapeutics an option to acquire exclusive global rights to an undisclosed preclinical bispecific T cell engager candidate.
- The license agreement includes upfront and near-term payments of approximately $20 million to Antengene, including cash and a minority equity stake in a K2 subsidiary.
- Antengene may receive up to $960.5 million in milestone payments and tiered royalties on sales related to ATG-106 under the agreement.
50 Articles
50 Articles
The Berkshire Eagle
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China Antengene…
Antengene licenses ATG-106 to K2 Therapeutics
BOSTON, SINGAPORE and HONG KONG, June 22, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: [6996 HK]), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it has entered into an exclusive license agreement ("Lic…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
